MedTrace Logo

A Master Protocol for Semaglutide Effects on Cardiovascular and Obesity-related Outcomes in People With Overweight or Obesity in the Real World

NCT07141914 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 285327

Last updated 2026-01-23

No results posted yet for this study

Summary

This study aims to evaluate the association of once-weekly semaglutide with the risk of cardiovascular (CV) and other obesity-related clinical outcomes in three study populations (Heart failure (HF), clinical Atherosclerotic Cardiovascular Disease (ASCVD), primary prevention).

This is a retrospective cohort study which includes administrative medical and pharmacy claims linked with clinical and laboratory measurements for participants in the US during January 1, 2016 - December 31, 2024.

Conditions

  • Overweight
  • Obesity
  • Heart Failure (HF)
  • Atherosclerotic Cardiovascular Disease (ASCVD)
  • Primary Prevention

Interventions

OTHER

No treatment given

No treatment given

OTHER

No treatment given

No treatment given

Sponsors & Collaborators

Principal Investigators

  • Clinical Transparency dept. 2834 · Novo Nordisk A/S

Eligibility

Min Age
45 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-08-29
Primary Completion
2025-12-19
Completion
2025-12-19

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07141914 on ClinicalTrials.gov